Orgenesis CEO to Participate in Webinar Panel on “New Approaches to COVID-19” on Thursday, September 10th
09 sept. 2020 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts
20 août 2020 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform
07 août 2020 07h30 HE
|
Orgenesis Inc.
Provides update on COVID-19 therapeutic programs Reports cash and cash equivalents of $97.5 million as of June 30, 2020 GERMANTOWN, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc....
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of T-Cells
14 juil. 2020 07h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis Added to Russell 3000® Index
29 juin 2020 08h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19
22 juin 2020 08h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Virus Spread and Protect Against Future Outbreaks such as COVID-19
10 juin 2020 09h07 HE
|
Orgenesis Inc.
GERMANTOWN, Md., June 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis to Collaborate with The Edith Wolfson Medical Center to Conduct Clinical Study Using Orgenesis’ Proprietary POCare Technologies for the Generation and Expansion of Tumor Infiltrating Lymphocytes
01 juin 2020 09h38 HE
|
Orgenesis Inc.
GERMANTOWN, Md., June 01, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...
Orgenesis Announces Collaboration with Hospital Infantil Universitario Niño Jesús, Madrid, to Establish Point of Care Center
22 mai 2020 09h11 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...
Orgenesis Announces Stock Repurchase Plan of Up to $10 Million
15 mai 2020 07h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and...